Effects from treating moderate- to high-risk obesity patients with anti-obesity medication from a societal perspective
Abstract Obesity is a global health concern with new medication treatment options. So far, research on how programs with newer anti-obesity medication (AOM) for the moderate- to high-risk population can mitigate the prevalence of obesity and reduce the economic burden of society is limited. We aimed...
Saved in:
| Main Authors: | Stephanie Reitzinger, Thomas Czypionka |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-97472-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of obesity medications in a young pediatric patient with optic nerve hypoplasia and severe early-onset obesity: A case reportEstablished FactsNovel Insights
by: Armine Simonian, et al.
Published: (2025-12-01) -
Novel findings regarding treatment obesity and weight-related comorbidities – the systemic literature review
by: Karina Urbańska, et al.
Published: (2025-01-01) -
Semaglutide: an emerging treatment option for patients with obesity related HFpEF
by: Sanya Ashraf Khaskheli, et al.
Published: (2024-08-01) -
Semaglutide and adenosine alleviate obesity-induced kidney injury, with observed modulation of the Txnip/NLRP3 pathway
by: Shuqi Wang, et al.
Published: (2025-05-01) -
Editorial: Insights in obesity: 2023
by: Katsunori Nonogaki
Published: (2024-11-01)